Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (9235V)
August 12 2020 - 5:30AM
UK Regulatory
TIDMHCM
RNS Number : 9235V
Hutchison China Meditech Limited
12 August 2020
Grant of Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August
12, 20 20 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq
/AIM : HCM) announces that on August 11, 20 20, it granted share
options under the Share Option Scheme conditionally adopted by
Chi-Med at its Annual General Meeting on April 24, 2015 (the "Share
Option Scheme"). The scheme limit of the Share Option Scheme was
refreshed on April 27, 2020.
Chi-Med granted share options under its Share Option Scheme to
employees to subscribe for a total of 1,155,000 Ordinary Shares
represented by 231,000 American Depositary Shares ("ADSs") (each
equating to five Ordinary Shares) subject to the acceptance of the
grantees. Details of such share options granted prescribed are as
follows:
Date of grant : August 11 , 2020
Exercise price of share options : US$32.82 per ADS
granted
Number of share options granted : 1,155,000 represented by 231,000
ADSs (five share options shall entitle
the holder thereof to subscribe
for one ADS)
Closing market price of ADSs : US$32.82 per ADS
on the date of grant
Validity period of the share : From August 11 , 2020 to August
options 10 , 2030
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGPUGPRUPUUBP
(END) Dow Jones Newswires
August 12, 2020 05:30 ET (09:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024